New breathing device could help COPD patients who reject standard machines
NCT ID NCT04840706
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a high-flow nasal cannula device (Airvo) in COPD patients with high carbon dioxide levels who could not or would not use standard non-invasive ventilation. The goal was to see if the device improved blood gas levels and reduced flare-ups over one year. Only 3 patients were enrolled before the study was terminated, so no firm conclusions can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- High-flow nasal cannula (Airvo) device
- What this could lead to
- If it works, this could offer a simpler breathing support option for COPD patients who cannot tolerate standard machines, potentially reducing hospital visits.
- What could go wrong
- The study was terminated early with only 3 participants, so results are very limited and may not apply to others. The device may not improve outcomes significantly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Turku University Hospital
Turku, 20521, Finland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test may curb antibiotic overuse in COPD attacks
- Can pressurized breathing boost mucus clearance in lung disease?
- HIV and hidden health risks: a major study probes the link
- Can tracking early COPD reveal ways to halt its progression?
- Smart inhaler coach: can an app perfect your breathing technique?
- Could everyday supplements shield your lungs?